Humanized tumor mice-A new model to study and manipulate the immune response in advanced cancer therapy

International Journal of Cancer

Volumn 129, Issue 9, 2011, Pages 2194-2206

  Wege, Anja K ^a   Ernst, Wolfgang ^a   Eckl, Judith ^b   Frankenberger, Bernhard ^b   Vollmann Zwerenz, Arabel ^a   Männel, Daniela N ^a   Ortmann, Olaf ^a   Kroemer, Alexander ^c   Brockhoff, Gero ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

ADCC; breast cancer; humanized tumor mice; immune based therapies; NK cells

Indexed keywords

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER MODEL; CANCER THERAPY; CELL MATURATION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOID ORGAN; MOUSE; NATURAL KILLER CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; T-LYMPHOCYTES;

EID: 80052265350     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26159     Document Type: Article

References (36)

1. Finn OJ,. Cancer immunology. N Engl J Med 2008; 358: 2704-15.
2. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K,. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98: 1275-80. (Pubitemid 46993549)
3. Mozaffari F, Lindemalm C, Choudhury A, Granstam-Björneklett H, Helander I, Lekander M, Mikaelsson E, Nilsson B, Ojutkangas ML, Osterborg A, Bergkvist L, Mellstedt H,. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer 2007; 97: 105-11. (Pubitemid 47012095)
4. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P,. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988; 54: 105-15.
5. Mestas J, Hughes CC,. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172: 2731-8. (Pubitemid 38263654)
6. Dalle S, Thieblemont C, Thomas L, Dumontet C,. Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 2008; 8: 523-32.
7. Harris M,. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5: 292-302. (Pubitemid 38541581)
8. Ishida T, Ishii T, Inagaki A, Yano H, Kusumoto S, Ri M, Komatsu H, Iida S, Inagaki H, Ueda R,. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia 2006; 20: 2162-8. (Pubitemid 44782842)
9. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K,. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64: 2127-33. (Pubitemid 38339463)
10. Kute TE, Savage L, Stehle JR Jr, Kim-Shapiro JW, Blanks MJ, Wood J, Vaughn JP,. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother 2009; 58: 1887-96.
11. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol 2009; 183: 4782-91.
12. Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγ(null) mouse model. Cancer Immunol Immunother 2009; 58: 1195-206.
13. Wulf-Goldenberg A, Eckert K, Fichtner I,. Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody. Cytotherapy 2011; 13: 108-13.
14. Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A,. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001; 61: 2177-82. (Pubitemid 32692044)
15. Sato F, Ito A, Ishida T, Mori F, Takino H, Inagaki A, Ri M, Kusumoto S, Komatsu H, Iida S, Okada N, Inagaki H, et al. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid. IL-2Rγ(null) mouse lymphoma model. Cancer Immunol Immunother 2010; 59: 1791-800.
16. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK, Melkus MW, Padgett-Thomas A, Zupancic M, Haase AT, Garcia JV,. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007; 204: 705-14. (Pubitemid 46631601)
17. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA, Wege AK, Haase AT, Garcia JV,. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006; 12: 1316-22. (Pubitemid 44706935)
18. Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV,. Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol 2008; 324: 149-65.
19. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV,. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 15: e16.
20. Macchiarini F, Manz MG, Palucka AK, Shultz LD,. Humanized mice: are we there yet? J Exp Med 2005; 202: 1307-11. (Pubitemid 41668732)
21. Kroemer A, Xiao X, Degauque N, Edtinger K, Wei H, Demirci G, Li XC,. The innate NK cells, allograft rejection, and a key role for IL-15. J Immunol 2008; 180: 7818-26.
22. Steinle A, Reinhardt C, Jantzer P, Schendel, DJ,. In vivo expansion of HLA-B35 alloreactive T cells sharing homologous T cell receptors: evidence for maintenance of an oligoclonally dominated allospecificily by persistent stimulation with an autologous MHC/peptide complex. J Exp Med 1995; 181: 503-513.
23. Kufer P, Zippelius A, Lutterbüse R, Mecklenburg I, Enzmann T, Montag A, Weckermann D, Passlick B, Prang N, Reichardt P, Dugas M, Köllermann MW, et al. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 2002; 62: 251-61. (Pubitemid 34074012)
24. Strowig T, Chijioke O, Carrega P, Arrey F, Meixlsperger S, Rämer PC, Ferlazzo G, Münz C,. Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood 2010; 116: 4158-67.
25. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, Corcuff E, Mortier E, Jacques Y, Spits H, Di Santo JP,. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009; 206: 25-34.
26. Münz C, Dao T, Ferlazzo G, de Cos MA, Goodman K, Young JW,. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood 2005; 105: 266-73. (Pubitemid 40053092)
27. Choudhary SK, Rezk NL, Ince WL, Cheema M, Zhang L, Su L, Swanstrom R, Kashuba AD, Margolis DM,. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{γ}c-/- mouse. J Virol 2009; 83: 8254-8.
28. Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, Tomizawa M, Doi T, Sone A, Suzuki N, Fujiwara H, Yasukawa M, Ishikawa F,. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r γ(null) humanized mice. Proc Natl Acad Sci USA 2010; 107: 13022-7.
29. Garrett JT, Rawale S, Allen SD, Phillips G, Forni G, Morris JC, Kaumaya PT,. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol 2007; 178: 7120-31. (Pubitemid 46847438)
30. Clynes RA, Towers TL, Presta LG, Ravetch JV,. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6. (Pubitemid 30208162)
31. Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szöllösi J,. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 2007; 6: 2065-72. (Pubitemid 47052497)
32. Shiokawa M, Takahashi T, Murakami A, Kita S, Ito M, Sugamura K, Ishii N,. In vivo assay of human NK-dependent ADCC using NOD/SCID/γc(null) (NOG) mice. Biochem Biophys Res Commun 2010; 399: 733-7.
33. Seitz G, Pfeiffer M, Fuchs J, Warmann SW, Leuschner I, Vokuhl C, Lang P, Handgretinger R, Armeanu-Ebinger S,. Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice. Oncol Rep 2010; 24: 1067-72.
34. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS,. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140: 36-45. (Pubitemid 350233246)
35. Waldmann TA,. IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Trends Mol Med 2003; 9: 517-21. (Pubitemid 38017189)
36. Boyiadzis M, Foon KA,. Natural killer cells: from bench to cancer therapy. Expert Opin Biol Ther 2006; 6: 967-70. (Pubitemid 44497120)